Clinical Trials Logo

Advanced Pancreatic Cancer clinical trials

View clinical trials related to Advanced Pancreatic Cancer.

Filter by:

NCT ID: NCT04931381 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer

Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to explore whether chemotherapy regimens guided by organoid drug sensitivity test can improve the outcomes of advanced pancreatic cancer. At the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response.

NCT ID: NCT04928625 Recruiting - Clinical trials for Advanced Pancreatic Cancer

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

Start date: August 6, 2021
Phase: Phase 1
Study type: Interventional

The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with with advanced pancreatic cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904

NCT ID: NCT04803851 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Start date: May 12, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.

NCT ID: NCT04643405 Recruiting - Clinical trials for Advanced Pancreatic Cancer

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Start date: March 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma. Dose Limiting Toxicities (DLTs) and maximum tolerated dose (MTD) of APG1387 in combination with nab-paclitaxel and gemcitabine will be evaluated in the dose escalation phase Ib. Safety and efficacy of APG1387 plus gemcitabine and nab-paclitaxel will be evaluated in phase II.

NCT ID: NCT04482257 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.

Start date: July 7, 2020
Phase: Phase 1
Study type: Interventional

Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover Bioequivalence Trial of Irinotecan Liposome Injection in Patients With Advanced Pancreatic Cancer.

NCT ID: NCT04239001 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Start date: February 2020
Phase: N/A
Study type: Interventional

A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: albumin paclitaxel, 120mg / m2, intravenous infusion for 30 minutes, D1. S-1, taken orally after meal, D1 - 14. (2) patients who met the input / discharge criteria were given jinyouli injections 24 hours after the end of intravenous infusion of albumin paclitaxel during the treatment period.

NCT ID: NCT04228601 Recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Start date: January 21, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The study is being conducted to: a) evaluate the tolerability and safety of the co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance Monotherapy in patients with advanced pancreatic cancer, and establish the maximum tolerated dose and recommended phase II dose of the combination; and b) assess the efficacy of the co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance Monotherapy in patients with advanced pancreatic cancer.

NCT ID: NCT04104672 Recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

ARC-8
Start date: November 6, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.

NCT ID: NCT04098081 Recruiting - Clinical trials for Advanced Pancreatic Cancer

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Start date: December 12, 2019
Phase: Phase 2
Study type: Interventional

Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma

NCT ID: NCT03889795 Recruiting - Clinical trials for Advanced Solid Tumor

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

Start date: June 5, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center trial in subjects with pancreatic cancer and other advanced solid tumors. It is an open-label, single arm dose escalation Phase IB trial with subjects accrued in a 3 subject dose escalation cohort. Subjects with treated advanced solid tumors, and showing disease progression on established standard therapy, will be enrolled in this trial.